GRDG's Fight: Help Fuel Global Cancer Research

I founded Global Research and Discovery Group in 2014 to serve as a private research and development organization that can apply rapid analysis and problem solving skills to quickly qualify, quantify, and solve the largest problems facing the world today. Basing my company's operational methods after BARDA we pride ourselves on being a nimble research team capable to focusing on solutions for the most pressing issues society is up against.

This isn't our first time taking on cancer. Before Moonshot my company developed the Linebacker 1 molecule which was very effective as a cancer treatment on it's own, however when combined with the top 4 cancer drugs on the market the drugs created what we have named the CRST-1 effect. CRST-1 dramatically increases the drug's ability to inhibit cancer growth . By itself the cancer drug Cisplatin was able to inhibit cancer cell growth by 23%, but when it was combined with LB-1 the two drugs inhibited cancer growth by 82%!

Now we are embarking on a research endeavor Mission Moonshot: Project MS-1. Moonshot is focused on pioneering a novel cancer prevention approach by tapping into the intricacies of the human body's innate immune system. Central to this endeavor is an in-depth exploration of beta cells and T cells, key components of the body's natural defense mechanisms. The MS-1 molecule will be the key to this new project.

In the intricate dance of the immune system, T cells are the immune system's warriors. These cells are adept at identifying abnormal or compromised cells, such as those in the initial stages of cancer development. Beta cells, on the other hand, play a crucial role as they act as the immune system's memory, keeping a record of all the battles your immune system has fought so that when those diseases return your T cells will have the knowledge to fight back.

The heart of Mission Moonshot lies in the creation and utilization of the MS-1 molecule. This innovative molecule will be designed to activate beta cells and stimulate T cells, essentially priming the innate immune system to recognize and target cancer growth. This project aims to intervene at the earliest stages of cancer, effectively thwarting its progression.

Our scientific advisor Dr. Roscoe Moore Jr, former Assistant Surgeon General of the United States and senior fellow at the Potomac Institute for Policy Studies, had this to say about our Mission Moonshot:

"I have been collaborating with Daryl Thompson at GRDG for almost eight years as a Senior Scientific Advisor. Daryl has created and developed multiple novel approaches to solutions for emerging public health concerns that have been successful. I am confident that Daryl and his team, given their track record of success, are poised to provide yet another potential breakthrough for cancer patients worldwide."

With our new project MS-1 we could do what we’ve done in the past, spend years in the bureaucratic process and working through all the red tape in order to perform the tests that we actually need or we could fast track things, get the funding to go straight to the important tests so that we can prove the efficacy of our MS-1 treatment and get this compound into the hands of a leading pharmaceutical company that can get it out of the discovery phase as soon as possible.